Avoid use of gadolinium unless the diagnostic information is essential and regular MRI studies are not available.All patients should be screened for renal dysfunction (kidney problems) by obtaining a history and if necessary laboratory test.When administering a gadolinium contrast agent, do not exceed the recommended dose outlined in the product labeling. 1285 Muscle Prior to any readministration of gadolinium there needs to be sufficient time for elimination of the gadolinium.The FDA is currently considering other risk management options in response to the discovery of gadolinium side effects in patients after undergoing MRI studies. Patients are strongly urged to contact their doctor immediately after receiving a gadolinium MRI if they have any of the following symptoms that may indicate the development of NSF:http://www.healthcaresup.com/1285-muscle/